---
title: "Keytruda (pembrolizumab) in high-risk early-stage triple-negative breast cancer: Indication questions"
description: "Indication questions on Keytruda (pembrolizumab) in high-risk early-stage triple-negative breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Drug names and Testing. Questions: What is KEYTRUDA (pembrolizumab) approved for in early-stage triple-negative breast cancer? Can KEYTRUDA QLEX (subcutaneous pembrolizumab) be used instead of IV KEYTRUDA for early-stage TNBC? What is the generic name of KEYTRUDA? Does PD-L1 expression affect KEYTRUDA eligibility in early-stage TNBC? 4 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/indication"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Keytruda (pembrolizumab) in high-risk early-stage triple-negative breast cancer: Indication questions

Manufacturer: Merck Sharp & Dohme LLC  
Prescribing information: [Keytruda](https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf)

## Indication

<a id="keytruda-early-tnbc-indication"></a>

### What is KEYTRUDA (pembrolizumab) approved for in early-stage triple-negative breast cancer?

> “KEYTRUDA and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection 165 mg + 2,000 units/mL are each indicated for the treatment of adult patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then each continued as a single agent as adjuvant treatment after surgery.”

Source: [KEYTRUDA: KEYNOTE-522 - Study Design & Clinical Findings, captured 2026-11-08](https://www.keytrudahcp.com/efficacy/early-stage-triple-negative-breast-cancer/#:~:text=KEYTRUDA%20and%20KEYTRUDA%20QLEX%E2%84%A2%20%28pembrolizumab,as%20adjuvant%20treatment%20after%20surgery.)

<a id="keytruda-qlex-substitution"></a>

### Can KEYTRUDA QLEX (subcutaneous pembrolizumab) be used instead of IV KEYTRUDA for early-stage TNBC?

> “The effectiveness of KEYTRUDA QLEX for its approved indications has been established based upon evidence from the adequate and well-controlled studies conducted with KEYTRUDA and additional data comparing the pharmacokinetic, efficacy, and safety profiles of KEYTRUDA QLEX and KEYTRUDA.”

Source: [KEYTRUDA: KEYNOTE-522 - Study Design & Clinical Findings, captured 2026-11-08](https://www.keytrudahcp.com/efficacy/early-stage-triple-negative-breast-cancer/#:~:text=The%20effectiveness%20of%20KEYTRUDA%20QLEX,of%20KEYTRUDA%20QLEX%20and%20KEYTRUDA.)

> “Pembrolizumab and berahyaluronidase alfa-pmph subcutaneous injection may be substituted for IV pembrolizumab. Pembrolizumab and berahyaluronidase alfa-pmph (KEYTRUDA QLEX) has different dosing and administration instructions compared to IV pembrolizumab (KEYTRUDA)”

Source: [KEYTRUDA: KEYNOTE-522 - Study Design & Clinical Findings, captured 2026-11-08](https://www.keytrudahcp.com/efficacy/early-stage-triple-negative-breast-cancer/#:~:text=Pembrolizumab%20and%20berahyaluronidase%20alfa%2Dpmph%20subcutaneous,compared%20to%20IV%20pembrolizumab%20%28KEYTRUDA%29)

## Drug names

<a id="keytruda-generic-name"></a>

### What is the generic name of KEYTRUDA?

> “KEYTRUDA<sup>®</sup> (pembrolizumab) injection, for intravenous use”

Source: [KEYTRUDA: Prescribing information, page 1, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf#page=1)

## Testing

<a id="keytruda-pd-l1-expression"></a>

### Does PD-L1 expression affect KEYTRUDA eligibility in early-stage TNBC?

> “Patients May be Eligible for a Regimen Including KEYTRUDA or KEYTRUDA QLEX Regardless of Tumor PD-L1 Expression”

Source: [KEYTRUDA: KEYNOTE-522 - Study Design & Clinical Findings, captured 2026-11-08](https://www.keytrudahcp.com/efficacy/early-stage-triple-negative-breast-cancer/#:~:text=Patients%20May%20be%20Eligible%20for,Expression)

> “Patients were enrolled regardless of tumor PD-L1 expression”

Source: [KEYTRUDA: KEYNOTE-522 - Study Design & Clinical Findings, captured 2026-11-08](https://www.keytrudahcp.com/efficacy/early-stage-triple-negative-breast-cancer/#:~:text=Patients%20were%20enrolled%20regardless%20of,expression)

Note: The first passage heads a hypothetical patient profile based on patients studied in KEYNOTE-522; the second is a KEYNOTE-522 inclusion criterion.

## Related pages
- [Medical information: Keytruda (pembrolizumab): High-risk early-stage triple-negative breast cancer](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer)
- [Pharmacology](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/safety)
- [Specific populations](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/guidelines)
